

# Taxiarchis Kourelis

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1712376/taxiarchis-kourelis-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

289  
papers

3,127  
citations

29  
h-index

46  
g-index

321  
ext. papers

4,147  
ext. citations

4.4  
avg, IF

5.1  
L-index

#	Paper	IF	Citations
289	Metformin and cancer: new applications for an old drug. <i>Medical Oncology</i> , <b>2012</b> , 29, 1314-27	3.7	205
288	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , <b>2017</b> , 129, 2111-2119	2.2	181
287	Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4319-24	2.2	146
286	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 59	7	115
285	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 578-598	6.4	88
284	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1323-1329	2.2	68
283	Activated peripheral blood and endothelial cells in thalassemia patients. <i>Annals of Hematology</i> , <b>2001</b> , 80, 577-83	3	64
282	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. <i>Blood</i> , <b>2017</b> , 129, 299-306	2.2	61
281	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , <b>2019</b> , 33, 531-536	10.7	60
280	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1123-1128	7.1	52
279	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 353-367	4.4	51
278	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , <b>2018</b> , 32, 2240-2249	10.7	49
277	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 187-194	7.1	45
276	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 908-917	6.4	43
275	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1417-1425	3	43
274	Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. <i>Leukemia</i> , <b>2019</b> , 33, 254-257	10.7	40
273	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 585-9	7.1	40

272	Tc2 response at the onset of COPD exacerbations. <i>Chest</i> , <b>2008</b> , 134, 483-488	5.3	37
271	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 984-8	7.1	37
270	Human mast cells stimulate activated T cells: implications for multiple sclerosis. <i>Annals of the New York Academy of Sciences</i> , <b>2008</b> , 1144, 74-82	6.5	36
269	A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. <i>Blood</i> , <b>2018</b> , 132, 670-672	2.2	33
268	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 472-483	6.4	33
267	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 1037-1046	6.9	32
266	IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. <i>European Journal of Dermatology</i> , <b>2010</b> , 20, 865-7	0.8	31
265	Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kappaB activation. <i>Journal of Molecular Endocrinology</i> , <b>2009</b> , 42, 397-405	4.5	30
264	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , <b>2019</b> , 33, 527-531	10.7	30
263	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 179-186	7.1	29
262	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 690-3	7.1	29
261	Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 1383-7	2.2	29
260	Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes. <i>Neurology</i> , <b>2019</b> , 93, e298-e305	6.5	28
259	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 375-8	7.1	28
258	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , <b>2017</b> , 49, 545-551	1.5	27
257	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 497-502	7.1	27
256	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , <b>2020</b> , 4, 3509-3519	7.8	27
255	MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E368-E370	7.1	26

254	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 588-594	4.5	26
253	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1020-1026	7.1	25
252	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 1051-4	7.1	25
251	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 32	7	22
250	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 55	7	22
249	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1146-1155	7.1	22
248	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , <b>2020</b> , 34, 1373-1382	10.7	22
247	POEMS Syndrome: Diagnosis and Investigative Work-up. <i>Hematology/Oncology Clinics of North America</i> , <b>2018</b> , 32, 119-139	3.1	22
246	Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 72	7	21
245	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 1284-9	4.3	21
244	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2020</b> , 27, 13-16	2.7	21
243	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , <b>2018</b> , 32, 712-718	10.7	20
242	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , <b>2019</b> , 3, 1930-1938	7.8	20
241	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , <b>2020</b> , 34, 1135-1143	10.7	19
240	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 20	7	18
239	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , <b>2018</b> , 32, 1811-1815	10.7	18
238	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 274-281	7.1	18
237	N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. <i>Leukemia</i> , <b>2020</b> , 34, 2749-2753	10.7	17

236	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 82	7	17
235	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 125	7	17
234	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , <b>2018</b> , 2, 3149-3154	7.8	17
233	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 310-315	7.1	16
232	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , <b>2019</b> , 33, 790-794	10.7	16
231	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , <b>2018</b> , 2, 769-776	7.8	16
230	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , <b>2019</b> , 33, 811-814	10.7	15
229	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1384-1393	7.1	15
228	Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , <b>2017</b> , 130, 1578-1584	2.2	15
227	Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. <i>Journal of Clinical Psychopharmacology</i> , <b>2011</b> , 31, 385-7	1.7	15
226	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , <b>2019</b> , 3, 744-750	7.8	15
225	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1518-1523	7.1	15
224	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 888-895	4.5	14
223	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 455-464	6.4	13
222	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E141-E143	7.1	13
221	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 106	7	13
220	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2360-2364	4.7	13
219	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 33	7	12

218	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 4	7	12
217	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2127-2132	4.7	12
216	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 56-58	6.4	12
215	Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. <i>Leukemia</i> , <b>2018</b> , 32, 719-728	10.7	12
214	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 98-105	4.5	12
213	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 864-864	2.2	12
212	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E222-E225	7.1	11
211	Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature. <i>American Journal of Hematology</i> , <b>2015</b> , 90, E183-4	7.1	11
210	A Proteomic Atlas of Cardiac Amyloid Plaques. <i>JACC: CardioOncology</i> , <b>2020</b> , 2, 632-643	3.8	11
209	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e108-e111	4.7	11
208	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , <b>2019</b> , 33, 730-738	10.7	11
207	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 435-440	7.1	10
206	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 701-707	4.5	10
205	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 1623-38	6.4	10
204	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , <b>2020</b> , 34, 1472-1475	10.7	10
203	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1280-1287	7.1	10
202	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 71-77	4.5	9
201	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1066-1071	7.1	9



200	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6581-6588	12.9	9
199	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 380-385	4.5	9
198	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 306-311	7.1	9
197	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , <b>2018</b> , 103, 1229-1234	6.6	8
196	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 889-894	7.1	8
195	Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab. <i>Acta Haematologica</i> , <b>2011</b> , 126, 40-3	2.7	8
194	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 304-304	2.2	8
193	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 50	7	8
192	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 1546-1577	6.4	8
191	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 587-594	4.4	7
190	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , <b>2020</b> , 4, 2236-2244	7.8	7
189	Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. <i>Blood Advances</i> , <b>2021</b> , 5, 1797-1804	7.8	7
188	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , <b>2019</b> , 33, 1273-1277	10.7	7
187	Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 2653-2659	6.1	7
186	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 2039-2050	4.4	6
185	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1520-1525	4.7	6
184	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 751-756	7.1	6
183	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 637-642	7.1	6

182	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 4-9	7.1	6
181	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1131-1136	7.1	6
180	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1775-1779	4.4	5
179	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2132-2137	4.4	5
178	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , <b>2018</b> , 32, 1421-1426	10.7	5
177	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 442-447	4.4	5
176	Reduced CD43 expression on the neutrophils of MDS patients correlates with an activated phenotype of these cells. <i>International Journal of Hematology</i> , <b>2001</b> , 73, 483-491	2.3	5
175	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , <b>2015</b> , 126, 4197-4197	2.2	5
174	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , <b>2016</b> , 128, 3337-3337	2.2	5
173	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , <b>2021</b> ,	10.7	5
172	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E8-E10	7.1	5
171	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 53-56	2	5
170	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 45	7	5
169	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. <i>Blood Advances</i> , <b>2021</b> , 5, 2101-2105	7.8	5
168	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , <b>2021</b> , 99, 707-715	9.9	5
167	Autologous stem cell transplantation for multiple myeloma patients aged $\geq 75$ treated with novel agents. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1144-1150	4.4	5
166	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , <b>2019</b> , 33, 1268-1272	10.7	4
165	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 52	7	4



164	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2019</b> , 26, 101-102	2.7	4
163	A simple additive staging system for newly diagnosed multiple myeloma.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 21	7	4
162	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene CiloleuceL Therapy for Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 4106-4106	2.2	4
161	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 677-687	6.4	4
160	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , <b>2021</b> , 35, 3604-3607	10.7	4
159	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , <b>2020</b> , 4, 322-326	7.8	4
158	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , <b>2021</b> , 35, 1428-1437	10.7	4
157	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2017</b> , 24, 40-41	2.7	3
156	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E507-E512	7.1	3
155	Improving strategies for the diagnosis of cardiac amyloidosis. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 945-61	2.5	3
154	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 596-601	2	3
153	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2157-2159	4.7	3
152	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , <b>2019</b> , 3, 1226-1229	7.8	3
151	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , <b>2019</b> , 125, 3574-3581	6.4	3
150	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 36-37	2.2	3
149	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , <b>2015</b> , 126, 3177-3177	2.2	3
148	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1077-1081	4.4	3
147	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 354-361	3.8	3

146	Non-cardiac biopsy sites with high frequency of transthyretin amyloidosis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 750-755	3.7	3
145	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 330-337	7.1	3
144	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , <b>2021</b> , 5, 1029-1036	7.8	3
143	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 377-387	6.4	3
142	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 446-454	7.1	3
141	"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 196	7	3
140	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2960-2967	1.9	2
139	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1402-1405 <sup>4.7</sup>	4.7	2
138	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 302-5	7.1	2
137	Describing the Cellular and Humoral Immune Tumor Microenvironment and Malignant Transcriptome across the Multiple Myeloma Disease Spectrum. <i>Blood</i> , <b>2020</b> , 136, 39-40	2.2	2
136	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. <i>Leukemia</i> , <b>2022</b> ,	10.7	2
135	Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. <i>Mayo Clinic Proceedings</i> , <b>2021</b> ,	6.4	2
134	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , <b>2019</b> , 134, 1846-1846	2.2	2
133	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4386-4386 <sup>2.2</sup>	2.2	2
132	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , <b>2020</b> , 136, 52-53	2.2	2
131	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	2
130	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , <b>2020</b> , 136, 12-13	2.2	2
129	Temozolomide Induced Bone Marrow Suppression- a Single Institution Outcome Analysis and Review of Literature. <i>Blood</i> , <b>2014</b> , 124, 1602-1602	2.2	2

128	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , <b>2021</b> , 138, 1639-1639	2.2	2
127	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3160-3160	2.2	2
126	The Clinical Impact of Proteomics in Amyloid Typing. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 1122-1127	6.4	2
125	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 451-460.e2	2	2
124	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 589.e1-589.e6		2
123	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 928-935	4.4	2
122	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 124	7	1
121	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1207-1210	7.1	1
120	Myeloid malignancy presenting with a platelet storage pool disorder. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1800-1	1.9	1
119	Mastocytosis causing refractory hypotension after coronary angiography. <i>International Journal of Cardiology</i> , <b>2012</b> , 156, e43-4	3.2	1
118	Trisomy 8 as the sole cytogenetic abnormality in an adult patient with acute lymphoblastic leukemia. <i>Cancer Genetics</i> , <b>2012</b> , 205, 337-8	2.3	1
117	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , <b>2020</b> , 136, 28-29	2.2	1
116	A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 9-10	2.2	1
115	Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 801851	5.3	1
114	Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. <i>Blood</i> , <b>2018</b> , 132, 1879-1879 <sup>1</sup>	2.2	1
113	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. <i>Blood</i> , <b>2019</b> , 134, 3510-3510	2.2	1
112	A Proteomic Atlas of Cardiac Amyloidosis. <i>Blood</i> , <b>2019</b> , 134, 1790-1790	2.2	1
111	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , <b>2019</b> , 134, 72-72	2.2	1

110	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , <b>2019</b> , 134, 4334-4334	2.2	1
109	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 1905-1905	2.2	1
108	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	1
107	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	1
106	Immunoglobulin Variable Region Family Usage and Outcomes of Patients with Systemic Light Chain Amyloidosis. <i>Blood</i> , <b>2014</b> , 124, 3402-3402	2.2	1
105	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 3444-3444	2.2	1
104	Ageing-associated immune system changes in multiple myeloma: The dark side of the moon. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 29, 100494	2	1
103	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 186	7	1
102	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , <b>2021</b> ,	7.1	1
101	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. <i>Blood</i> , <b>2021</b> , 138, 3838-3838	2.2	1
100	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , <b>2021</b> ,	10.7	1
99	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2018</b> , 132, 2884-2884	2.2	1
98	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , <b>2019</b> , 134, 1800-1800	2.2	1
97	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , <b>2019</b> , 134, 5490-5490	2.2	1
96	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E60-E62	7.1	1
95	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8895-8901	4.8	1
94	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2975-2979	1.9	1
93	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 316-322	1.9	1

92	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. <i>Clinical Biochemistry</i> , <b>2021</b> , 97, 67-73	3.5	1
91	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 158	7	1
90	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 944-954	6.4	0
89	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 79-83	4.5	0
88	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , <b>2020</b> , 136, 31-32	2.2	0
87	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , <b>2018</b> , 132, 4460-4460	2.2	0
86	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , <b>2020</b> , 136, 48-49	2.2	0
85	Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study. <i>Blood</i> , <b>2021</b> , 138, 401-401	2.2	0
84	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 3760-3760	2.2	0
83	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 2711-2711	2.2	0
82	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , <b>2021</b> , 138, 3774-3774	2.2	0
81	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , <b>2021</b> , 138, 568-568	2.2	0
80	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , <b>2019</b> , 134, 3171-3171	2.2	0
79	Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 741-742	7.5	0
78	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , <b>2021</b> , 5, 2753-2759	7.8	0
77	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 274-277	4.4	0
76	Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E35-E38	7.1	0
75	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 433-436	3.8	0

74	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 3011-3018	1.9	o
73	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 770.e1-770.e7		o
72	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 59	7	o
71	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 62	7	o
70	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-6	1.9	o
69	Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , <b>2017</b> , 2017, 6803804	0.7	
68	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 27-28	2.2	
67	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. <i>Blood</i> , <b>2020</b> , 136, 17-18	2.2	
66	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , <b>2020</b> , 136, 44-45	2.2	
65	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 15-16	2.2	
64	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , <b>2020</b> , 136, 14-15	2.2	
63	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , <b>2020</b> , 136, 6-7	2.2	
62	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
61	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
60	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥75 Treated with Novel Agents. <i>Blood</i> , <b>2020</b> , 136, 12-13	2.2	
59	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	
58	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. <i>Blood</i> , <b>2020</b> , 136, 15-15	2.2	
57	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2020</b> , 136, 41-42	2.2	



56	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study. <i>Blood</i> , <b>2020</b> , 136, 6-8	2.2
55	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , <b>2021</b> , 138, 2707-2707	2.2
54	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNENIS). <i>Blood</i> , <b>2021</b> , 138, 1333-1333	2.2
53	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , <b>2021</b> , 138, 2700-2700	2.2
52	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio $\geq 100$ . <i>Blood</i> , <b>2021</b> , 138, 1617-1617	2.2
51	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , <b>2021</b> , 138, 819-819	2.2
50	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , <b>2021</b> , 138, 3805-3805	2.2
49	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 1750-1750	2.2
48	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , <b>2021</b> , 138, 3773-3773	2.2
47	Histopathologic Characterization of Vexas Syndrome. <i>Blood</i> , <b>2021</b> , 138, 4656-4656	2.2
46	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , <b>2021</b> , 138, 3761-3761	2.2
45	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 1632-1632	2.2
44	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , <b>2021</b> , 138, 2691-2691	2.2
43	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 1619-1619	2.2
42	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , <b>2021</b> , 138, 543-543	2.2
41	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , <b>2021</b> , 138, 1630-1630	2.2
40	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , <b>2021</b> , 138, 119-119	2.2
39	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 2650-2650	2.2

- 38 Long-Term Survivorship with Active Multiple Myeloma. *Blood*, **2018**, 132, 1912-1912 2.2
- 37 Comparative Analysis of Staging Systems in AL Amyloidosis. *Blood*, **2018**, 132, 3228-3228 2.2
- 36 Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3159-3159
- 35 Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3158-3158 2.2
- 34 Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449 2.2
- 33 Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. *Blood*, **2018**, 132, 2147-2147 2.2
- 32 Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. *Blood*, **2018**, 132, 3226-3226
- 31 Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. *Blood*, **2018**, 132, 4613-4613 2.2
- 30 Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. *Blood*, **2018**, 132, 4497-4497 2.2
- 29 Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). *Blood*, **2018**, 132, 4502-4502 2.2
- 28 Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 1902-1902 2.2
- 27 Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. *Blood*, **2018**, 132, 5594-5594 2.2
- 26 Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. *Blood*, **2018**, 132, 3227-3227 2.2
- 25 Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. *Blood*, **2018**, 132, 5610-5610 2.2
- 24 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2018**, 132, 3268-3268 2.2
- 23 Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. *Blood*, **2018**, 132, 3436-3436 2.2
- 22 Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2018**, 132, 4615-4615 2.2
- 21 Patient-Reported Outcome Driven Case Management System for Hematology In Prospective Study. *Blood*, **2018**, 132, 719-719 2.2

20	PS1397 OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA. <i>HemaSphere</i> , <b>2019</b> , 3, 641	0.3
19	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4505-4505	2.2
18	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , <b>2019</b> , 134, 5523-5523	2.2
17	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4396-4396	2.2
16	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , <b>2019</b> , 134, 3080-3080	2.2
15	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 5833-5833	2.2
14	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 1904-1904	2.2
13	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. <i>Blood</i> , <b>2019</b> , 134, 1770-1770	2.2
12	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , <b>2019</b> , 134, 5532-5532	2.2
11	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 2197-2197	2.2
10	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , <b>2019</b> , 134, 2013-2013	2.2
9	Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study. <i>Blood</i> , <b>2015</b> , 126, 5192-5192	2.2
8	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 1194-1194	2.2
7	Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study. <i>Blood</i> , <b>2016</b> , 128, 5476-5476	2.2
6	Outcome of Very Young (≤40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , <b>2016</b> , 128, 5576-5576	2.2
5	Defective Peripheral Blood Endothelial Cell Progenitors in Patients with Scleroderma and Psoriatic Arthritis. <i>Blood</i> , <b>2008</b> , 112, 4724-4724	2.2
4	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 3209-3209	2.2
3	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 309.e1-309.e5	

2	Amyloid light-chain deposition in a schwannoma. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , <b>2021</b> , 26, 101301	0.5
1	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. <i>Bone Marrow Transplantation</i> , <b>2022</b> ,	4-4